Cipla's Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Cipla Ltd reported a 8.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.5%.
- Its expenses for the quarter were up by 10.3% QoQ and 10.1% YoY.
- The net profit increased 4.8% QoQ and increased 3.7% YoY.
- The earnings per share (EPS) of Cipla Ltd stood at 16.72 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 7858.39 | 7216.03 | 7241.63 | 8.9% | 8.5% |
Total Expenses | 6004.86 | 5446.10 | 5452.57 | 10.3% | 10.1% |
Profit Before Tax | 1853.53 | 1769.93 | 1789.06 | 4.7% | 3.6% |
Tax | 500.46 | 477.88 | 483.04 | 4.7% | 3.6% |
Profit After Tax | 1353.37 | 1291.61 | 1305.01 | 4.8% | 3.7% |
Earnings Per Share | 16.72 | 16.06 | 16.12 | 4.1% | 3.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Cipla Ltd is a global pharmaceutical company headquartered in India. It is known for manufacturing a wide range of pharmaceutical products, including prescription drugs, over-the-counter products, and active pharmaceutical ingredients (APIs). Cipla operates in various therapeutic areas such as respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system medications. The company has a significant presence in both domestic and international markets, providing affordable medicines across the globe. As of the latest available data, there are no specific recent developments provided, but Cipla continues to expand its product portfolio and strengthen its market position through strategic initiatives and collaborations.
Revenue
In the second quarter of the fiscal year 2026 (Q2FY26), Cipla Ltd reported a total income of ₹7858.39 crores. This represents a quarter-over-quarter (QoQ) increase of 8.9% from ₹7216.03 crores in Q1FY26 and a year-over-year (YoY) increase of 8.5% from ₹7241.63 crores in Q2FY25. The company has shown consistent revenue growth over the quarters, reflecting its robust operational performance and market demand for its products. The revenue growth is indicative of Cipla's ability to maintain its market presence and expand its reach in the pharmaceutical industry.
Profitability
Cipla Ltd's profit before tax for Q2FY26 was ₹1853.53 crores, which is a 4.7% increase QoQ from ₹1769.93 crores in Q1FY26 and a 3.6% increase YoY from ₹1789.06 crores in Q2FY25. The profit after tax stood at ₹1353.37 crores, marking a 4.8% increase QoQ from ₹1291.61 crores and a 3.7% increase YoY from ₹1305.01 crores. The company's earnings per share (EPS) for Q2FY26 was ₹16.72, up 4.1% QoQ from ₹16.06 and 3.7% YoY from ₹16.12. These figures reflect Cipla's effective cost management and operational efficiency, contributing to its profitability growth.
Operating Metrics
Total expenses for Cipla Ltd in Q2FY26 amounted to ₹6004.86 crores, which is a 10.3% increase QoQ from ₹5446.10 crores in Q1FY26 and a 10.1% increase YoY from ₹5452.57 crores in Q2FY25. The tax paid during the quarter was ₹500.46 crores, consistent with the profit before tax growth, showing a 4.7% increase QoQ and a 3.6% increase YoY. These operating metrics indicate Cipla's capacity to manage its expenditures while maintaining its revenue growth, which is crucial for sustaining long-term profitability. The increase in total expenses aligns with the revenue growth, suggesting a proportional scaling of operations.